Format

Send to

Choose Destination
See comment in PubMed Commons below
Mediators Inflamm. 2014;2014:342524. doi: 10.1155/2014/342524. Epub 2014 Mar 20.

Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis.

Author information

1
Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France.
2
Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Clinical Department for Osteoarticular Diseases, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.
3
Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
4
Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Département d'Hématologie, CHU Saint Eloi, 80 Avenue Augustin Fliche, 34295 Montpellier, France ; UMR-CNRS 5235, Université Montpellier II, Place Eugène Bataillon, 34095 Montpellier, France.
5
Inserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Unité des Maladies Autoinflammatoires, Laboratoire de Génétique, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.

Abstract

Although biologic therapies have changed the course of rheumatoid arthritis (RA), today's major challenge remains to identify biomarkers to target treatments to selected patient groups. Circulating micro(mi)RNAs represent a novel class of molecular biomarkers whose expression is altered in RA. Our study aimed at quantifying miR-125b in blood and serum samples from RA patients, comparing healthy controls and patients with other forms of rheumatic diseases and arthritis, and evaluating its predictive value as biomarker for response to rituximab. Detectable levels of miR-125b were measured in total blood and serum samples and were significantly elevated in RA patients compared to osteoarthritic and healthy donors. The increase was however also found in patients with other forms of chronic inflammatory arthritis. Importantly, high serum levels of miR-125b at disease flare were associated with good clinical response to treatment with rituximab three months later (P = 0.002). This predictive value was not limited to RA as it was also found in patients with B lymphomas. Our results identify circulating miR-125b as a novel miRNA over expressed in RA and suggest that serum level of miR-125b is potential predictive biomarker of response to rituximab treatment.

PMID:
24778468
PMCID:
PMC3980876
DOI:
10.1155/2014/342524
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center